| Vol. 6.40 – 22 November, 2021 |
| |
|
|
| Genetic fate mapping results revealed that a subset of cardiac endothelial cells transiently expressed αSMA and Zeb1 during embryonic valve formation and transdifferentiated into mesenchymal cells through EndoMT. [Circulation] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| The authors identified the protein syndesmos to specifically interact with cZNF292 in endothelial cells by RNA affinity purification and subsequent mass spectrometry analysis. [Circulation Research] |
|
|
|
| VE-cadherin was an essential scaffolding protein to maintain pro-lymphangiogenic signaling nodes at the plasma membrane, which was required for the development and adult maintenance of cardiac lymphatics, but not for cardiac function basally or after injury. [Circulation Research] |
|
|
|
| In primary endothelial cells, investigators showed that glyoxal induced cell cycle perturbation and that carboxymethyllysine modification reduced acetylation of tubulins and impaired microtubule dynamics. [Nature Communications] |
|
|
|
| Researchers presented an integrated chip-based optical nanoscopy combined with quantitative phase microscopy to obtain 3D morphology of liver sinusoidal endothelial cells. [Proceedings of the National Academy of Sciences of the United States of America] |
|
|
|
| Scientists identified leukemia inhibitory factor (LIF) as a mitogen for bovine choroidal endothelial cell (EC), although LIF had been mainly characterized as an EC growth inhibitor and an anti-angiogenic molecule. [EMBO Molecular Medicine] |
|
|
|
| The authors examined whether pure fetal mesenchymal stromal cells and endothelial colony-forming cells from the human term placenta were neuroprotective through modulating neuroinflammation and supporting the brain vasculature. [NPJ Regenerative Medicine] |
|
|
|
| In the type 1 diabetic NOD mouse model, engineered growth factors improved both re-epithelialization and granulation tissue formation. [NPJ Regenerative Medicine] |
|
|
|
| Investigators found that in terms of metabolic activity, endothelial cells were much more sensitive to PFOS than fibroblasts or epithelial cells, and concluded that PFOS possesses antiangiogenic properties. [Environmental Pollution] |
|
|
|
| Scientists captured a novel mechanism by which inflammatory perivascular adipose tissue compensated severe endothelial dysfunction by contributing nitric oxide upon cholinergic stimulation. [Vascular Pharmacology] |
|
|
|
| Immunocytochemical analysis confirmed SULF1/SULF2 expression in endothelial cell lining of blood vessels and in developing cardiomyocytes, but not in the adult cardiomyocytes despite persisting at reduced levels in the adult endothelial cells. [Scientific Reports] |
|
|
|
| An optimized combination of enzymatic solutions with mechanical scrapping was used to remove the amniotic epithelium and chorion trophoblastic layer of a placenta membrane, which resulted in exposing the basement membranes of both sides without their separation and subsequent damages to the in-between spongy layer. [Scientific Reports] |
|
|
|
| Vitronectin receptor (VTNR)-expressing HUVECs were used to determine the effects of endocrine disrupting chemicals and endogenous hormones on cell adhesion to vitronectin-coated surfaces, and on VTNR activation. [Toxicology in Vitro] |
|
|
|
|
| The authors characterize the features and mechanisms of coronary microembolization and discuss the clinical trials of drugs and devices for prevention and treatment. [Nature Reviews Cardiology] |
|
|
|
| Scientists describe how microenvironmental tissue-specific biophysical, biochemical, immune, and inflammatory cues dictate the specialization of endothelial cells with zonated functions. [Developmental Cell] |
|
|
|
| Investigators describe how microenvironmental tissue-specific biophysical, biochemical, immune, and inflammatory cues dictate the specialization of endothelial cells with zonated functions. [Developmental Cell] |
|
|
|
|
| Denali Therapeutics, Inc. announced that its strategic partner Takeda Pharmaceutical Company Limited has exercised an option to co-develop and co-commercialize DNL593, an investigational, brain-penetrant progranulin replacement therapy for the potential treatment of frontotemporal dementia-granulin. [Denali Therapeutics, Inc.] |
|
|
|
|
| January 16 – 20, 2022 Banff, Alberta, Canada |
|
|
|
|
|
| Accession Therapeutics – Oxford, England, United Kingdom |
|
|
|
| University of California Los Angeles – Los Angeles, California, United States |
|
|
|
| The University of Sheffield – Sheffield, England, United Kingdom |
|
|
|
| The University of British Columbia – Vancouver, British Columbia, Canada |
|
|
|
| Columbia University – New York, New York, United States |
|
|
|
|